Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports

The Firm is evaluating Tylenol lawsuits on behalf of individuals who allegedly suffered acetaminophen liver damage, allegedly due to Tylenol-brand medications.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInShare on PinterestEmail a friend
Free Case Review
Our Firm is currently investigating a number of Tylenol lawsuits on behalf of individuals who allegedly suffered serious liver damage due to the acetaminophen in Tylenol products. We are pleased to see this litigation moving forward.

New York, New York (PRWEB) July 12, 2014

Tylenol lawsuits (http://www.tylenollawsuitcenter.com/) involving liver damage allegations continue to move forward in the federal multidistrict litigation underway in U.S. District Court, Eastern District of Pennsylvania, Bernstein Liebhard LLP reports. According to a filing dated July 1, 2014, U.S. District Judge Lawrence F. Stengel has ordered the deposition of a former McNeil-PPC president. Among other things, Judge Stengel found that the witness’s testimony concerning the marketing of Tylenol was “clearly relevant” to plaintiffs’ misbranding claims. (In Re: Tylenol (Acetaminophen) Marketing, Sales Practices and Products Liability Litigation, MDL No. 2436)

“Our Firm is currently investigating a number of Tylenol lawsuits on behalf of individuals who allegedly suffered serious liver damage due to the acetaminophen in Tylenol products. We are pleased to see this litigation moving forward,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is offering free legal reviews to consumers who were allegedly harmed by a Tylenol-brand over-the-counter medication.

Tylenol Liver Damage Litigation
According to court documents, more than 140 Tylenol liver damage claims are currently pending in the litigation underway in the Eastern District of Pennsylvania. All of the lawsuits were filed on behalf of individuals who allegedly suffered injuries due to acetaminophen in Tylenol products. In many cases, plaintiffs claim that liver damage occurred even though the drugs were used in accordance with label directions, and resulted in hospitalization, the need for liver transplantation or death.

According to the U.S. Food & Drug Administration (FDA), acetaminophen, the active ingredient in Tylenol products, was the leading cause of acute liver failure in the U.S. between 1998 and 2003.* The Philadelphia Inquirer recently reported that 78,000 people require emergency room care every year due to toxic reactions to acetaminophen. Such injuries also result in about 33,000 hospitalizations every year.**

In April, the FDA announced that prescription drugs containing more than 325 milligrams of acetaminophen were no longer considered safe and were being voluntarily removed from the market. *** However, according to a Bloomberg.com report, over-the-counter Extra Strength Tylenol caplets each contain 500 mg of acetaminophen. Last year, McNeil Consumer Healthcare announced that it would add new, more prominent warnings regarding the risk of liver damage to the labels of Tylenol-brand medication.****

Victims of serious liver injuries allegedly related to the use of a Tylenol product may be entitled to compensation for the physical and financial damages they have suffered. To learn more about the potential link between Tylenol and liver damage, please visit Bernstein Liebhard LLP's website. Free, confidential and no-obligation case reviews are available by calling 800-511-5092.

*http://www.fda.gov/downloads/forconsumers/consumerupdates/ucm172664.pdf, FDA, 2009
**articles.philly.com/2014-02-17/news/47382323_1_acetaminophen-poisoning-tylenol-maker-kate-trunk, Philadelphia Inquirer, February 17, 2014
***latimes.com/science/sciencenow/la-sci-sn-extra-strength-acetaminophen-fda-20140428-story.html, LA Times, April 28, 2014
****bloomberg.com/news/2013-08-29/j-j-adds-warning-to-tylenol-caps-on-acetaminophen-risk.html, Bloomberg.com, August 29, 2013

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.tylenollawsuitcenter.com/
https://plus.google.com/115936073311125306742?rel=author